Stock Charts
WallstreetSelect
Symbol Lookup

WallStreetSelect 114
Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Search InvestCenter
Recent Quotes
My Watchlist
Indicators
Local Stocks
IR Biosciences Holdings, Inc. (OP: IRBS)
0.0075 USD  UNCHANGED
Streaming Delayed Price  /  Updated: 9:46 AM EDT, May 21, 2013  /  Add to My Watchlist      
View: Quote News
All news about IR Biosciences Holdings, Inc.
 
LOTE, GOFF and WFMC added to EPR's Active OTC Watch List
April 25, 2013
from ACCESSWIRE
Standard and Poor’s Worst Mistake Yet
August 08, 2011
category Week/Ahead , Rating/Agencies , Editors/Picks , and 1 more.
from Wall Street Greek
Scancell Develops New Vaccine for the Treatment of Lung Cancer
June 30, 2011
from Business Wire News Releases
ImmuneRegen BioSciences(R) Reports Positive Results in Cancer Vaccine Studies in Radboud University Collaboration
October 28, 2010
from GlobeNewswire News Releases
ImmuneRegen BioSciences(R) Reports Scancell Collaboration Yielding Positive Results in Cancer Vaccine Studies of Homspera(R)
September 08, 2010
from GlobeNewswire News Releases
Scancell Holdings Plc (‘Scancell Holdings’ or the ‘Company’) Collaboration With ImmuneRegen BioSciences® Yields Positive Results in Cancer Vaccine Studies
September 07, 2010
from Business Wire News Releases
ImmuneRegen BioSciences(R) Invited to Submit Full Proposal to BARDA for Homspera(R) as a Potential Medical Countermeasure for Injury Associated With Radiation Exposure
August 31, 2010
Multi-year Proposal to be Submitted for Advanced Research and Development of Homspera(R) as Medical Treatment Disease Resulting From Radiation Exposure Read More
from GlobeNewswire News Releases
University of Rochester Medical Center Receives $15 Million in Government Funding to Research ImmuneRegen's Homspera(R)
August 25, 2010
Five-year Grant Continues Research on Homspera(R) as a Radiation-Induced Injury Countermeasure Read More
from GlobeNewswire News Releases
/ CORRECTION - ImmuneRegen BioSciences
August 05, 2010
from Marketwired News Releases
ImmuneRegen BioSciences Completes Successful Reduction of Debt
August 04, 2010
Reorganizes Nearly $10 Million Debt Into $6 Million Equity at 30 Cents and $3.6 Million of Restructured Convertible Debt Read More
from Marketwired News Releases
Scancell Enters Strategic Collaboration with ImmuneRegen BioSciences®
June 04, 2010
from Business Wire News Releases
ImmuneRegen BioSciences(R) Announces Collaboration With the Department of Tumor Immunology of the Radboud University Nijmegen Medical Centre, the Netherlands
April 27, 2010
Radboud University Researchers to Evaluate Homspera(R) in Cancer Vaccine Studies; Expand on Previous Immunoregulatory Findings Read More
from Marketwired News Releases
The Week in Review: Innovation
April 24, 2010
The first SEED Life Sciences Business Plan Competition chose as its winner Dr. Yuqiang Wang from Guangzhou Jinan University College of Pharmacy; Sanofi-Aventis opened an R&D center in Shanghai which... Read More
from ChinaBio® Today
NeoStem, Inc. and ImmuneRegen BioSciences(R) Announce a Collaborative Agreement to Advance Stem Cell Technology
April 22, 2010
from PR Newswire
NeoStem and ImmuneRegen to Collaborate on Stem Cells
April 22, 2010
NeoStem, Inc. announced a stem cell collaboration with ImmuneRegen BioSciences, Inc., a wholly owned subsidiary of IR BioSciences Holdings, Inc. (OTCBB: IRBS). NeoStem will investigate whether... Read More
from ChinaBio® Today
ImmuneRegen BioSciences(R) Initiates Strategic Collaboration With MPI Research to Accelerate Clinical Development of Lead Indications
April 21, 2010
from Marketwired News Releases
ImmuneRegen BioSciences(R) Retains Redwood Consultants, LLC to Assist in Shareholder Relations and Strategic Planning
April 19, 2010
from Marketwired News Releases
ImmuneRegen BioSciences Submits Homspera(R) for FDA Orphan Drug Product Designation for the Treatment of Idiopathic Pulmonary Fibrosis
March 04, 2010
Company to Continue Developmental Work on Idiopathic Pulmonary Fibrosis in Conjunction With the University of Rochester Read More
from Marketwired News Releases
Fred Hutchinson Cancer Research Center Initiates Studies on ImmuneRegen BioSciences' Cancer Therapy Candidate
February 10, 2010
Fred Hutchinson Cancer Research Center to Evaluate Homspera(R) in Novel Cancer Therapy Model; Expand on Previous Homspera Findings in the Domain of Cancer Immunotherapy Read More
from Marketwired News Releases
National Cancer Institute Initiates Studies on ImmuneRegen BioSciences' Vaccine Adjuvant Candidate
January 27, 2010
NIH to Evaluate Homspera(R) in Novel Anti-HIV Mucosal Vaccine Model; Expand on Previous Homspera Findings Read More
from Marketwired News Releases
IR Biosciences' ImmuneRegen (OTCBB: IRBS) Getting Attention for Its Adult Stem Cell Active Compound
January 26, 2010
from Marketwired News Releases
ImmuneRegen BioSciences(R) Reports Additional Positive Results From Study of Homspera(R) in Treating Highly Pathogenic Influenza
January 05, 2010
New Data Reveal Homspera Reduced the Levels of Influenza Virus Particles in Infected Animals Read More
from Marketwired News Releases
ImmuneRegen BioSciences(R) Summarizes Previous 9 Months of Advances as Homspera(R) Development Continues
December 24, 2009
from Marketwired News Releases
ImmuneRegen BioSciences'(R) Reports Efficacy of a New Adjuvant of a Preventive Cancer Vaccine
December 21, 2009
Editor's Note: This Is the Corrected Version of a Press Release That Clarifies and Restates a Previous Press Release That Was Issued on Dec. 14. Read More
from Marketwired News Releases
ImmuneRegen BioSciences'(R) Drug Candidate Homspera Confirms Efficacy as Cancer Vaccine Adjuvant
December 14, 2009
Homspera Treatment Significantly Reduces Growth of Tumors and Improves Survival in Melanoma Study Read More
from Marketwired News Releases
ImmuneRegen BioSciences(R) Reports Positive Results of Homspera(R) in Treating Highly Pathogenic Influenza
November 10, 2009
Homspera Improves Survival and Reduces Symptoms of Highly Lethal Influenza Virus Infection Without Any Additional Treatment Read More
from Marketwired News Releases
ImmuneRegen BioSciences(R) to Further Homspera(R) Research in Study Funded by U.S. Government
October 22, 2009
Experiment to Further Define Drug's Role in Mitigating Lung Damage and Lung Infection Read More
from Marketwired News Releases
ImmuneRegen BioSciences(R) Initiates Homspera(R) Studies Against Global Influenza Threat
October 12, 2009
This Continues Studies Previously Sponsored by ImmuneRegen Testing the Efficacy of Homspera in Treating the Novel H1N1 ("Swine Flu") Influenza Strain Read More
from Marketwired News Releases
ImmuneRegen BioSciences(R) Announces Strategic Partnership With Azopharma Product Development Group, Inc.
September 23, 2009
from Marketwired News Releases
ImmuneRegen BioSciences(R) Announces Partnership With Bachem, Inc., for Manufacturing of Homspera(R)
September 22, 2009
from Marketwired News Releases
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here

©2009 WALL STREET SELECT | Online Media Select, LLC | Privacy Policy | Terms | Advertise | Contact Us